Volume 7.24 | Jul 3

Immune Regulation News 7.24 July 3, 2015
Immune Regulation News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Like Us on Facebook  IRN on Twitter
His and Hers Pain Circuitry in the Spinal Cord
New research reveals for the first time that pain is processed in male and female mice using different cells. These findings have far-reaching implications for our basic understanding of pain, how we develop the next generation of medications for chronic pain—which is by far the most prevalent human health condition—and the way we execute basic biomedical research using mice. [Press release from The Hospital for Sick Children discussing online prepublication in Nature Neuroscience] Press Release | Abstract
Automate your cell isolations and increase laboratory throughput with RoboSep™-S. Explore features!
PUBLICATIONS (Ranked by impact factor of the journal)
Diversification of Memory B Cells Drives the Continuous Adaptation of Secretory Antibodies to Gut Microbiota
Scientists found that mice and humans exhibited longitudinal persistence of clonally related B cells in the IgA repertoire despite major changes in the microbiota during antibiotic treatment or infection. [Nat Immunol] Abstract

Inflammation-Induced Formation of Fat-Associated Lymphoid Clusters
Fat-associated lymphoid clusters contributed to the retention of B-1 cells in the peritoneal cavity through high expression of the chemokine CXCL13, and they supported B cell proliferation and germinal center differentiation during peritoneal immunological challenges. [Nat Immunol] Abstract

Retinoic Acid Differentially Regulates the Migration of Innate Lymphoid Cell Subsets to the Gut
The authors report that prior to migration to the intestine innate lymphoid cells first undergo a “switch” in their expression of homing receptors from lymphoid to gut homing receptors. This process is regulated by mucosal dendritic cells and the gut-specific tissue factor retinoic acid. [Immunity] Abstract | Graphical Abstract

Endogenous Toll-Like Receptor 9 Regulates AKI by Promoting Regulatory T Cell Recruitment
A series of reconstitution and depletion studies defined a role for Toll-like receptor 9 in maintaining regulatory T cell-mediated homeostasis in cisplatin-induced AKI. [J Am Soc Nephrol] Abstract

Reversal of New-Onset Type 1 Diabetes with an Agonistic TLR4/MD-2 Monoclonal Antibody
Researchers showed that an agonistic monoclonal antibody to TLR4/MD-2 reverses new-onset diabetes in a high percentage of diabetic non-obese diabetic mice. [Diabetes] Abstract

Metal-Specific CD4+ T-Cell Responses Induced by Beryllium Exposure in HLA-DP2 Transgenic Mice
Investigators characterized the T-cell receptor (TCR) repertoire of beryllium (Be)-responsive CD4+ T cells derived from the lungs of Be oxide-exposed HLA-DP2 transgenic mice. The majority of Be-specific T-cell hybridomas expressed TCR Vβ6, and a subset of these hybridomas expressed identical or nearly identical β-chains that were paired with different α-chains. [Mucosal Immunol] Abstract

Adaptive Immune-Like γ/δ T Lymphocytes Share Many Common Features with Their α/β T Cell Counterparts
By comparing the other subsets to naive and memory CD8+ α/β T cells, researchers showed that Ly-6C− or + CD44lo and Ly-6C+CD44hi γ/δ T cells greatly resemble, and behave like, their CD8+ α/β T cell counterparts. [J Immunol] Abstract

Targeting Antigen to Clec9A Primes Follicular Th Cell Memory Responses Capable of Robust Recall
Scientists provide definitive evidence that Clec9A targeting promotes the development of follicular Th cells (TFH) by showing that responding CD4 T cells express CXCR5, PD1, the TFH transcription factor Bcl6, and the cytokine IL-21, and that these cells localize to germinal centers. [J Immunol] Abstract

Don’t forget to subscribe to Human Immunology News and Immunology of Infectious Disease News!

It all starts with the right cells! Access a range of fresh and frozen human primary cells.
Innate Lymphoid Cells in the Initiation, Regulation and Resolution of Inflammation
The authors discuss the emerging family of innate lymphoid cells (ILCs), the role of ILCs in inflammation, and how current or novel therapeutic strategies could be used to selectively modulate ILC responses and limit chronic inflammatory diseases. [Nat Med] Abstract

Visit our reviews page to see a complete list of reviews in the immune regulation research field.
Biomedical Sciences Institute Researcher Receives $1.6 Million to Develop Anti-Inflammatory Drug
Dr. Jian-Dong Li, a professor and director of the Institute for Biomedical Sciences at Georgia State University and a Georgia Research Alliance Eminent Scholar in Inflammation and Immunity, has received a five-year, $1.6 million federal grant to develop novel anti-inflammatory therapeutics against middle-ear infections. [Georgia State University] Press Release

Vitae Pharmaceuticals Announces Initiation of a Phase I Single Ascending Dose Study of VTP-43742 in Autoimmune Disorders
Vitae Pharmaceuticals, Inc. announced the initiation of a Phase I single ascending dose clinical trial of VTP-43742, the company’s wholly owned and potential first-in-class RORγt inhibitor for the treatment of autoimmune disorders, including psoriasis, multiple sclerosis, and various arthropathies, as well as rare and orphan disorders. [Vitae Pharmaceuticals, Inc.] Press Release

European Commission Approves Bristol-Myers Squibb’s Opdivo (Nivolumab), the First and Only PD-1 Checkpoint Inhibitor Approved in Europe, for Both First-Line and Previously-Treated Advanced Melanoma Patients
Bristol-Myers Squibb Company announced that the European Commission has approved Opdivo, a PD-1 immune checkpoint inhibitor, for the treatment of advanced (unresectable or metastatic) melanoma in adults, regardless of BRAF status. [Bristol-Myers Squibb Company] Press Release

TxCell Announces FDA Acceptance of IND for Ovasave
TxCell SA announced that the United States Food and Drug Administration (FDA) has accepted TxCell’s Investigational New Drug (IND) application for the company’s lead product, Ovasave®, currently in a Phase IIb clinical trial for the treatment of patients with refractory Crohn’s disease. [TxCell SA] Press Release

STEMCELL Technologies Launches Innovative Products to Support CAR T Cell Research
STEMCELL Technologies Inc. announced the launch of ImmunoCult™ Human T Cell Activator reagents and ImmunoCult™-XF T Cell Expansion Medium to support T cell researchers in their goal to develop CAR T cell immunotherapeutics. The products provide significant benefits compared to existing technologies. [STEMCELL Technologies Inc.] Press Release

From our sponsor: Free Nature Reviews Immunology poster – Immune Response to HIV. Request a copy.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Immunogenicity and Bioassay Summit 2015
November 17-19, 2015
Baltimore, United States

Visit our events page to see a complete list of events in the immune regulation community.
NEW Postdoctoral Researcher – Tumorigenesis and Immune Response (Nationwide Children Hospital-Ohio)

Scientist – Immunology and Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Scientific Marketing Specialist – Immunology (STEMCELL Technologies Inc.)

Senior Scientist – Immunology (Valera LLC)

Scientist – Immunology Discovery (Genentech, Inc.)

Postdoctoral Fellow – Antibody Engineering/Immuno-Oncology (California Institute for Biomedical Research)

Associate Director/Director – Immunology (Valera)

Postdoctoral Fellow – Immune Reconstitution in Hematopoietic Stem Cell Transplantation (Stanford University)

Process Facilitator (Opexa Therapeutics)

Postdoctoral Fellow – Immune Tolerance (Stanford University)

Assistant Professor – Immunology (Northwestern University)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Immune Regulation News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Immune Regulation News: Archives | Events | Contact Us